Independent predictors of mortality for critically ill patients with polytrauma: a single center, retrospective study - Zhou P, Ling L, Xia X, Yuan H, Guo Z, Feng Q, Ma J.
Independent predictors of mortality and transfusion therapy in polytrauma patients from the Chinese population remain unknown. Here, we aimed to identify these predictors by retrospectively collecting and analyzing vital signs and laboratory results for 40... (Source: SafetyLit)
Source: SafetyLit - February 22, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

ICMR seeks proposals, to fund plasma therapy trials at 20 govt facilities
ICMR will choose 20 healthcare facilities, largely government-run hospitals, across India to begin clinical trials for convalescent plasma transfusion therapy, a treatment that is being explored for critically-ill Covid-19 patients. (Source: The Economic Times)
Source: The Economic Times - April 22, 2020 Category: Consumer Health News Source Type: news

Analysis of transfusion therapy during the March 2019 mass shooting incident in Christchurch, New Zealand - Badami KG, Mercer S, Chiu M, Yi M, Warrington S.
We describe and analyse the transfusion management of these casualties. METHODS: Data on demographic... (Source: SafetyLit)
Source: SafetyLit - March 16, 2020 Category: International Medicine & Public Health Tags: Disaster Preparedness Source Type: news

Corticosteroids Impair Granulocyte Transfusion Therapy By Targeting NET Formation and Neutrophil Antifungal Functions Via ROS/Dectin1 Pathways
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 21, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Bethesda transfusion therapy company raises $2.7 million
A Bethesda medical technology company focused on developing innovations in the transfusion industry has raised $2.7 million in an equity funding round. Hemanext, which changed its corporate name in October from New Health Sciences Inc., was seeking to raise a total of $5 million, a Securities and Exchange Commission filing shows. Hemanext did not specify was the proceeds of the funding will be used for. I've reached out to Hemanext for comment a nd will update this story when I hear back. The company… (Source: Health Care:Physician Practices headlines)
Source: Health Care:Physician Practices headlines - December 20, 2017 Category: American Health Authors: Tina Reed Source Type: news

Terumo launches Mirasol pathogen reduction tech trial
This study is intended as a step towards improving transfusion therapy and transfusion safety in the U.S. We’re excited to be a part of this study that hopefully will lead to measures that could further protect the nation’s blood supply from certain complications and threats of blood transfusions,” Miplate lead investigator Dr. Sherrill Slichter of Bloodworks Northwest said in a prepared statement. The study is expected to take 3.5 years and will include involvement from up to 15 hospitals and blood centers as well as 556 patients, the company said. Eligible patients in the trial will have a platelet co...
Source: Mass Device - May 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Terumo Source Type: news